成人午夜又粗又硬又长_鲁一鲁AV2019在线_欧美深深色噜噜狠狠yyy_www.91色.com_色影音先锋av资源网_特级做A爰片久久毛片A片喷水_99精品无人区乱码1区2区3区_国产人妻久久精品一区_欧美午夜精品久久久久久浪潮_av免费无码天堂在线_蜜桃色欲AV久久无码精品软件_日美一级毛片_久久久久久久久性潮_国产乱对白精彩_日韩精品免费一区二区_亚洲欧美精品在线_无码国产69精品久久久久_开心五月综合激情综合五月_干一夜综合_亚洲中文有码字幕日本

    最近美國癌癥學會（American Association for Cancer Research， AACR）發表一項研究認為近幾年來NIH的經費一再削減被認為將嚴重阻礙癌癥的研究。由于基因組學的迅猛發展，人們發現癌癥已經不像過去那樣不可攻克，然而目前美國國家經費投入的短缺卻可能會阻礙這一進程。根據AACR的報告，美國NIH的研究經費已經連續數年降低。相較于十年前，NIH的經費縮水了20%以上。2013年，NIH的研究經費僅有290億美元，因此2013年也成為了自2001年以來，NIH自助研究項目最少的一年。
    據此，AACR表示，NIH對生物醫藥領域的投資對疾病研究有著極其重要的作用。僅在過去的18個月，已經有13種癌癥藥物獲得批準。而目前已經有41種不同癌癥靶點的藥物獲得FDA批準，而五年前和十年前這一數字分別僅為17、5。因此，美國政府應當慎重思考權衡相關政策。（藥家網yaojia.org）
    詳細英文報道：
    Years of flat funding from the National Institutes of Health plus across-the-board federal spending cuts known as sequestration could have deleterious effects for cancer research, says a new study by the American Association for Cancer Research (AACR).
    While cancer treatment has seen incredible progress in recent years because of advances in genomics research, weakening federal investment could adversely affect the ability of scientists to carry out current research projects, reduce the number of new grant proposals that the National Cancer Institute can support and result in fewer job opportunities young researchers entering the field.
    According to the AACR report, the amount of annual funding for NIH has been less than what is needed to keep pace with biomedical inflation. In the late 1990s, following a period of stagnant budgets, Congress ramped up medical research funding for 5 years. But in the 10 years since the doubling ended in 2003, the NIH budget has been steadily shrinking.
    On top of that, the sequester cuts rolled out in March 2013 slashed the NIH budget by $1.6 billion, just over 5%. The impact to the National Cancer Institute was a cutback of $239 million, according to the AACR report, which was presented to Congress March 13.
    "Despite the $1 billion in funds that were restored to the NIH and NCI in January, these agencies' budgets remain far below what they were in fiscal year 2012 because of sequestration. And when taking into account medical inflation, NIH's ability to fund lifesaving research has been cut by more than 20% over the past decade," AACR CEO Dr. Margaret Foti said in a statement.
    The report found that at the reduced fiscal year 2013 funding level of $29 billion, the NIH is now funding the lowest number of research projects since fiscal year 2001.
    The AACR said that support for biomedical research translates directly to improvements in care for patients, citing 13 new cancer drug approvals in the past 18 months and 6 new drug indications for different types of cancer. In addition, there are now 41 FDA-approved therapies that target specific molecules involved in cancer, compared with 17 target therapies 5 ago and just 5 a decade ago.